Tamsulosin hydrochloride + Solifenacin succinate

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder

Trial Timeline

Oct 1, 2008 โ†’ Jan 1, 2010

About Tamsulosin hydrochloride + Solifenacin succinate

Tamsulosin hydrochloride + Solifenacin succinate is a approved stage product being developed by Astellas Pharma for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00771394. Target conditions include Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00771394ApprovedCompleted

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors